Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cyclobenzaprine + caffeine is a combination of two active pharmaceutical ingredients. Cyclobenzaprine is a skeletal muscle relaxant that acts primarily at the brainstem to reduce muscle spasms of local origin, commonly used for relief of muscle spasm associated with acute musculoskeletal conditions. Caffeine is a central nervous system stimulant that can counteract drowsiness and sedation caused by cyclobenzaprine. The combination has been proposed and patented as a treatment for muscle spasm, aiming to maintain the efficacy of cyclobenzaprine while reducing its sedative side effects by including caffeine[5][1]. Cyclobenzaprine’s mechanism involves antagonism at serotonin and histamine receptors in the central nervous system, while caffeine acts as an adenosine receptor antagonist.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cyclobenzaprine + caffeine.